{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:12Z","timestamp":1791414132529,"version":"4.3.3"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Iclaprim, a novel dihydrofolate reductase inhibitor, inhibited 90% of the clinical isolates (MIC\n            <jats:sub>90<\/jats:sub>\n            ) of\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            (\n            <jats:italic>n<\/jats:italic>\n            = 785) collected by a national surveillance program at a concentration of 1 \u03bcg\/ml. The MIC\n            <jats:sub>90<\/jats:sub>\n            for iclaprim was 7 doubling dilutions lower for trimethoprim-sulfamethoxazole-susceptible isolates (\n            <jats:italic>n<\/jats:italic>\n            = 670; MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.06 \u03bcg\/ml) than for trimethoprim-sulfamethoxazole-resistant isolates (\n            <jats:italic>n<\/jats:italic>\n            = 115; MIC\n            <jats:sub>90<\/jats:sub>\n            , \u22658 \u03bcg\/ml). The potential clinical utility of iclaprim to treat patients with pneumococcal infections may depend upon the current prevalence of resistance to trimethoprim-sulfamethoxazole in this pathogen.\n          <\/jats:p>","DOI":"10.1128\/aac.01388-08","type":"journal-article","created":{"date-parts":[[2009,1,13]],"date-time":"2009-01-13T02:10:53Z","timestamp":1231812653000},"page":"1690-1692","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["In Vitro Activity of Iclaprim against Respiratory and Bacteremic Isolates of\n            <i>Streptococcus pneumoniae<\/i>"],"prefix":"10.1128","volume":"53","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jac\/dkm242","volume":"60","year":"2007","unstructured":"Andrews, J., D. Honeybourne, J. Ashby, G. Jevons, A. Fraise, P. Fry, S. Warrington, S. Hawser, and R. Wise. 2007. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg\/kg of iclaprim (AR-100) in healthy men. J. Antimicrob. Chemother.60:677-680.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2005.07.001"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg457"},{"key":"e_1_3_1_5_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2006"},{"key":"e_1_3_1_6_2","unstructured":"Performance standards for antimicrobial susceptibility testing; 2007 vol. 27"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.10.052"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1885-1886.2004"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-925524"},{"key":"e_1_3_1_10_2","first-page":"8","volume":"120","year":"2008","unstructured":"Sahm, D. F., N. P. Brown, D. C. Draghi, A. T. Evangelista, Y. C. Yee, and C. Thornsberry. 2008. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad. Med.120(Suppl. 1):8-15.","journal-title":"Postgrad. Med."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.07.023"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1358\/dof.2004.029.03.785046","volume":"29","year":"2004","unstructured":"Sorbera, L. A., J. Castaner, and X. Rabasseda. 2004. Iclaprim (AR-100, Ro-48-2622). Drugs Future29:220-225.","journal-title":"Drugs Future"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.275-280.2004"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qco.0000235161.85925.e8"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1867-1874.2003"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2006.08.005","volume":"28","year":"2006","unstructured":"Zhanel, G. G., X. Wang, K. Nichol, A. Nikulin, A. Wierzbowski, M. Mulvey, and D. J. Hoban. 2006. Canadian pediatric multi-drug resistant Streptococcus pneumoniae from 1998-2004: epidemiology evolution and characterization. Int. J. Antimicrob. Agents28:465-471.","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01388-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01388-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:50:23Z","timestamp":1645473023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01388-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1128\/AAC.01388-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01388-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"2008-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-01-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}